Rua Bioscience Ltd. 2024 AR2
The report outlines Rua Bioscience's progress in the fiscal year 2024, highlighting its transition to a capital-light strategy focused on genetics and distribution. The company expanded its distribution agreements in Germany, Australia, and the United Kingdom, and secured approvals for new products in New Zealand. Additionally, Rua Bioscience advanced its social impact initiatives, including the Compassionate Access Programme and scholarship offerings in the Tairawhiti community. On the environmental front, the company completed its third annual greenhouse gas emissions audit, expanding its Scope 3 reporting to include purchased goods and services.
Company: Rua Bioscience Ltd.
Sector: Manufacturing
Country: New Zealand
Year: 2024
Type: AR2
Pages: 92
Back to company
Rua Bioscience Ltd.
Annual Report
The report outlines Rua Bioscience's progress in the fiscal year 2024, highlighting its transition to a capital-light strategy focused on genetics and distribution. The company expanded its distribution agreements in Germany, Australia, and the United Kingdom, and secured approvals for new products in New Zealand. Additionally, Rua Bioscience advanced its social impact initiatives, including the Compassionate Access Programme and scholarship offerings in the Tairawhiti community. On the environmental front, the company completed its third annual greenhouse gas emissions audit, expanding its Scope 3 reporting to include purchased goods and services.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jul 1, 2023 - Jun 30, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Women on Board
Women in Management
Employees